Traders should monitor upcoming clinical milestones: readout from the CLBP Phase 3 trial later this year, initiation of the DMD registrational trial, and site activation in the adult SR-aGvHD study. The CAR technology acquisition could enhance product potency and create long-term value, but near-term revenue will be driven by Ryoncil® adoption.
Price Chart
Executive Summary
Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close of enrollment in its Phase 3 trial for chronic low back pain (CLBP), received FDA clearance for a registrational trial in pediatric Duchenne muscular dystrophy (DMD), and acquired a patented CAR technology platform from Mayo Clinic to enhance its MSC therapies. The updates were shared during its R&D Day webcast.
Key Financial Metrics
Key Facts
- Ryoncil® is approaching $100 million in net revenue since its launch last year.
- Enrollment in the Phase 3 trial for chronic low back pain (CLBP) is closing at the end of the month.
- FDA cleared an IND to proceed directly to a registrational trial for Ryoncil® in pediatric DMD.
- Central IRB approval obtained for adult SR-aGvHD trial; first sites to activate this quarter.
- Acquired a patented CAR technology platform from Mayo Clinic to enhance MSC-based therapies.
Financial Impact
Ryoncil® nearing $100M in net revenue indicates growing commercial traction; DMD and CLBP programs represent significant future revenue potential.
Risk Factors
- Clinical trial setbacks in CLBP, DMD, or SR-aGvHD could delay approvals.
- Regulatory delays or rejections despite IND clearance.
- Forward-looking statements carry uncertainty; actual results may differ materially.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270209 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access